Drug Information

Drug General Information
Drug ID
D0A2BO
Former ID
DIB003121
Drug Name
S-110
Synonyms
SGI-110; DNA demethylating agent (myelodysplastic syndrome), Supergen
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 3 [525074]
Company
SuperGen Inc
Structure
Download
2D MOL

3D MOL
Canonical SMILES
OC[C@@H]1[C@@H](OP(=O)(OC[C@H]2O[C@@H](n3c4nc([nH]c(=O)<br />c4nc3)N)C[C@@H]2O)[O-])C[C@@H](O1)n1c(=O)nc(nc1)N.[Na+]
Target and Pathway
Target(s) DNMT1 Target Info Inhibitor [530893]
KEGG Pathway Cysteine and methionine metabolism
Metabolic pathways
MicroRNAs in cancer
Pathway Interaction Database Regulation of retinoblastoma protein
PathWhiz Pathway Methionine Metabolism
Reactome PRC2 methylates histones and DNA
NoRC negatively regulates rRNA expression
DNA methylation
WikiPathways Trans-sulfuration and one carbon metabolism
Retinoblastoma (RB) in Cancer
One Carbon Metabolism
Trans-sulfuration pathway
References
Ref 525074ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
Ref 530893S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.